HC Wainwright just gave Arcus Biosciences (Arcus Biosciences (RCUS)) a big vote of confidence. The firm raised its price target from $32 to $45—a 33% jump—and kept a Buy rating. The reason? The company's drug casdatifan is being positioned for a much larger market than previously thought.

Arcus is going all-in on first-line clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer. In its first-quarter earnings release, the company laid out a strategy to make casdatifan a backbone therapy in ccRCC. That means combining it with the standard-of-care regimen—anti-PD-1 plus anti-CTLA-4—to potentially become a go-to treatment from the start.

The company is already enrolling patients in a cohort of the Phase 1/1b ARC-20 study. The goal is to generate enough data to kick off a Phase 3 trial by the end of 2026. It's an aggressive timeline, but Arcus is clearly betting big on casdatifan's potential.

Analyst Emily Bodran's new price target includes revenue from casdatifan in the first-line setting, on top of what she had already modeled for patients who have already been treated with immunotherapy (post-IO) in both first-line and second-line settings. She now assumes about $2.2 billion in peak global unadjusted revenues for the first-line opportunity, and roughly $2 billion for the post-IO market.

But she's not ignoring the risks. Because the first-line program is still early, Bodnar applies a lower probability of success (POS) of 30%. That's partly because a recent trial of a competing combo—Merck's Keytruda plus Lenvima plus Welireg—failed to meet its primary endpoint in a similar setting. That failure highlights how tough it is to develop new treatments for ccRCC.

Still, Bodnar believes casdatifan is different from Merck's Welireg (belzutifan). She points to casdatifan's greater potency and pharmacodynamic effect, which has already shown best-in-class efficacy in later-line settings. If that translates to first-line, the upside could be huge.

Investors seem to agree. Arcus shares were up 4.71% at $27.95 on Monday, reflecting optimism around the updated outlook.

Of course, early-stage biotech is never a sure thing. But with a clear strategy, a differentiated drug, and a big market opportunity, Arcus is making a compelling case—and HC Wainwright is buying it.